<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535455</url>
  </required_header>
  <id_info>
    <org_study_id>A118121</org_study_id>
    <nct_id>NCT02535455</nct_id>
  </id_info>
  <brief_title>Acceptance and Compassion to Enhance Self-care Pilot</brief_title>
  <acronym>ACES Pilot</acronym>
  <official_title>Development and Pilot of Positive Self-Reappraisal Emotion Regulation Intervention to Improve Self-Care Among HIV+ Substance Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Innovative approaches are needed to optimize the benefits of treatment as prevention (TasP)
      among HIV+ substance users, who experience profound health disparities that amplify onward
      transmission risk. This project will systematically develop, refine and conduct an open pilot
      to assess the feasibility and acceptability of a two-phase emotion regulation intervention
      that targets emotional barriers to HIV-related self-care among individuals who endorse active
      substance use. Emotional barriers such as shame and internalized stigma have been identified
      as barriers to optimal HIV care among individuals struggling with HIV and substance use. To
      effectively implement TasP, strategies for addressing these barriers are needed. Utilizing
      transdiagnostic approaches (e.g., positive affect-focused emotional regulation, mindfulness
      and self-compassion) investigators will develop, refine and pilot a two-phase emotional
      regulation intervention that requires only 5 face-to-face hours and can ultimately be
      implemented by a case-management-level staff person or trained peer educator. The first phase
      of the intervention will be a multicomponent in-person intervention targeting emotional,
      cognitive and behavioral barriers to HIV self-care behaviors among HIV+ substance users. The
      second phase of the intervention will extend the intervention benefits by sending
      personalized positive self-reappraisal text messages in response to text message queries
      about participants' mood. This phase will use an innovative personalized bi-directional
      platform, which will leverage an existing text message delivery system. This project will be
      instrumental in developing a relatively low-resource intervention strategy to address unmet
      emotional barriers to optimal HIV-care among individuals who are actively using substances.
      This work will provide the necessary pilot data for a subsequent grant submission to assess
      the preliminary efficacy of the intervention. The resulting intervention has the potential to
      address emotional barriers to self-care along the HIV care cascade: including retention in
      care, antiretroviral treatment adherence and persistence, and ultimately viral suppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will develop and refine a two-phase emotion regulation intervention. This
      process will involve 5 steps: 1) conducting 5-8 key informant interviews, including obtaining
      feedback on a drafted manual and materials from providers and case managers, 2) integrating
      the qualitative data, 3) running 2 participants through a condensed version of the
      intervention and obtaining feedback on the content, language, and text message interface, 4)
      integrating the additional feedback, and 5) conducting an open pilot with 20 participants to
      assess feasibility and acceptability of the revised intervention. The pilot will include 4
      research assessment visits which will involve completion of self-report questionnaires using
      Qualtrics at baseline, within one week of completion of phase 1, within one week of
      completing phase 2, and 4-months following the completion of phase 1. Viral load (VL) and CD4
      tests will be assessed at baseline and VL will be assessed again at the 4-month follow up.

      Qualitative interviews. The investigators will conduct 5-8 semi-structured qualitative
      interviews with providers and case managers. Interviews will inquire about unmet
      psychological barriers to HIV-care, perceptions of proposed domains and text message
      questions and response options. All interviews will be recorded, transcribed and analyzed
      using thematic analysis. Prominent themes and suggestions brought up in the interviews will
      be integrated into the intervention materials and implementation.

      Trial run of pilot. After integrating the feedback from the key informant interviews,
      investigators will recruit two participants to complete a condensed version of the
      intervention. After each of the 5 sessions, participants will be asked to complete perceived
      usefulness surveys. Both participants will then be interviewed to obtain feedback on the
      intervention. These interviews will be recorded, transcribed and analyzed using thematic
      analysis. Prominent themes and suggestions brought up in these interviews as well as logistic
      challenges will be integrated into the intervention materials and implementation procedures.

      Text messages. Investigators will use questions adapted from a previously published
      personalized bi-directional text message intervention involving HIV+ substance users (TxText)
      to assess mood, adherence and substance use. Each participant will receive 3 texts/week
      inquiring about current mood over the course of the intervention. Additionally, in phase 2
      each participant will receive weekly texts asking about their medication adherence. Given the
      stigmatized nature of substance use, investigators will use a coded query, adapted from
      TxText, which assess substance use in the form of a weather question. This coded query
      strategy has demonstrated feasibility and acceptability among a similar population of HIV+
      active substance users. All participants will be reminded of the meaning of this question
      during phase 1. During the last in-person intervention visit, participants will identify 5
      positive self-reappraisal statements and link them to response options to the mood query
      based on when they feel each would be most helpful in regulating their emotions. Throughout
      phase 2, participants will then receive their linked positive-self reappraisal statements in
      response to mood queries. Participants will then be asked to respond on a 6-point scale
      indicating how helpful the positive self-reappraisal was (0=extremely unhelpful to 5=
      extremely helpful), which will be used to assess engagement in phase 2 of the intervention.

      HIV disease markers. Blood samples of 35mL peripheral venous blood sample will be obtained at
      baseline and the final follow-up visit to assess viral load. CD4 count will be assessed at
      baseline to provide personalized feedback on HIV-related self-care. A total of 44 blood
      sample will be obtained, 2 for each participant in the pilot.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline antiretroviral adherence to post intervention follow up visits</measure>
    <time_frame>Collected at baseline, research visit after face-to-face intervention component (approximately 5 weeks post-baseline) and research visit after text-message component (approximately 13 months post-baseline).</time_frame>
    <description>Participants will be asked to complete the Visual Analogue Scale (VAS) in person at baseline and subsequent research visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline engagement in HIV-related Care (number of HIV-related health visits scheduled and attended) to follow up visits.</measure>
    <time_frame>Collected at baseline, research visit after face-to-face intervention component (approximately 5 weeks post-baseline) and research visit after text-message component (approximately 13 months post-baseline).</time_frame>
    <description>Participants will be asked to report the number of HIV-related health visits scheduled and attended. Additionally, chart reviews will be conducted at the end of the study to determine the number of attended compared to scheduled HIV-related health visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline viral load to final follow up visit.</measure>
    <time_frame>Collected at baseline and approximately 21 months post-baseline at final research visit.</time_frame>
    <description>Participants will have blood drawn for viral load tests at baseline and their final follow up visit. The values will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in substance use</measure>
    <time_frame>Assessed at baseline, approximately 5 weeks post-baseline, approximately 13 months post-baseline and approximately 21 months post-baseline.</time_frame>
    <description>The ASSIST measures substance use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline sexual risk behaviors to research visit after face-to-face intervention component (approximately 5 weeks post-baseline) and research visit after text-message component (approximately 11 months post-baseline).</measure>
    <time_frame>Assessed at baseline, approximately 5 weeks post-baseline, approximately 13 months post-baseline and approximately 21 months post-baseline.</time_frame>
    <description>Self-report questions to assess recent sexual risk behaviors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV and Abuse Related Shame (HARSI)</measure>
    <time_frame>Assessed at baseline, approximately 5 weeks post-baseline, approximately 13 months post-baseline and approximately 21 months post-baseline.</time_frame>
    <description>The HARSI is a self report measure that assesses HIV and abuse related shame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression (CES-D)</measure>
    <time_frame>Assessed at baseline, approximately 5 weeks post-baseline, approximately 13 months post-baseline and approximately 21 months post-baseline.</time_frame>
    <description>The CES-D will be used to assess self-reported depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-Compassion (Self-Compassion Scale)</measure>
    <time_frame>Assessed at baseline, approximately 5 weeks post-baseline, approximately 13 months post-baseline and approximately 21 months post-baseline.</time_frame>
    <description>The Self-Compassion Scale will be used to assess self-reported self compassion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mindfulness (Five Facet Mindfulness Questionnaire)</measure>
    <time_frame>Assessed at baseline, approximately 5 weeks post-baseline, approximately 13 months post-baseline and approximately 21 months post-baseline.</time_frame>
    <description>The Five Facet Mindfulness Questionnaire will be use to assess self-reported mindfulness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Substance Use Disorder</condition>
  <arm_group>
    <arm_group_label>ACES Pilot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ACES Pilot</intervention_name>
    <description>This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).</description>
    <arm_group_label>ACES Pilot</arm_group_label>
    <other_name>Acceptance and Compassion to Enhance Self-care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English-speaking

          -  HIV+

          -  â‰¥18 years old

          -  Able to complete informed consent

          -  Endorse polysubstance use in the past 2 months, excluding cannabis and tobacco

          -  Participants must own a cell phone with text message capacity and be willing to work
             with a study staff member to add minutes or money to their cell phone plan to cover
             the text-message component of the intervention (at no cost to participants).

          -  Consent to release their medical records, in order to assess engagement in HIV-care
             (i.e., attended/scheduled appointments).

        Exclusion Criteria:

          -  Endorsement of active suicidality or psychosis on initial clinical interview.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abigail W Batchelder, PhD, MPH</last_name>
    <phone>917-940-1283</phone>
    <email>abigail.batchelder@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam W Carrico, PhD</last_name>
    <email>adam.carrico@ucsf.edu</email>
  </overall_contact_backup>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Abigail Batchelder, PhD, MPH</investigator_full_name>
    <investigator_title>Postdoctoral Scholar</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

